NYSE
$178.88▼ 0.14%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $10.51BShares out 58.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 10.7After-hours26.10.08 08:074Ownership#●●●
GLAUKOS Corp
Tomas Navratil, an executive at Glaukos Corp, reported a change in beneficial ownership of securities on October 5, 2026. This filing is a standard Form 4 disclosure regarding changes in insider stock holdings.…more
$178.88-0.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:08144Ownership
GLAUKOS Corp
Tomas Navratil, an insider at Glaukos Corp, has filed an SEC Form 144 to report a proposed sale of company shares. This filing serves as a standard notification of an insider's plan to dispose of their holdings.…more
$178.88-0.14%vs prev closeView filingShare - 9.28After-hours26.09.29 07:234Ownership
GLAUKOS Corp
Tomas Navratil, an executive at Glaukos Corp, reported a change in beneficial ownership of securities on September 25, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more
$178.88-0.14%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Regular26.10.10 01:49#●●●#●●●
Glaukos Reports Successful Phase 4 Results for iDose TR Eye Therapy
Glaukos achieved its primary efficacy goals in a Phase 4 clinical trial, demonstrating superior intraocular pressure reduction when combining iDose TR with cataract surgery. The therapy offers a long-term solution to improve patient compliance compared to traditional daily eye drops.…more
$178.88-0.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.9Pre-market26.10.09 20:06
●●●●●●●● ●●●●● ●●●●●●
Glaukos reported that its Phase 4 trial for iDose TR, when used with cataract surgery, successfully met its primary endpoint by demonstrating superior intraocular pressure reduction. The study confirms the treatment's efficacy and safety profile, supporting its potential to improve standard glaucoma care.…more
$178.88-0.14%vs prev closeShareBenzinga - 10.8Regular26.10.09 01:49
●●●●●●●● ●●●●● ●●●●●●
Glaukos announced successful three-year trial results for its non-invasive keratoconus treatment, Epioxa, demonstrating long-term corneal stabilization. Additionally, the company secured an exclusive licensing agreement to develop a new tri-specific biologic for various retinal diseases.…more
$178.88-0.14%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report